159 related articles for article (PubMed ID: 37328745)
1. Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report.
Faiq S; Lavelle K; Hu T; Shoback D; Ku G
BMC Endocr Disord; 2023 Jun; 23(1):133. PubMed ID: 37328745
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet attenuates hypercalcemia observed in mice bearing either Rice H-500 Leydig cell or C26-DCT colon tumors.
Colloton M; Shatzen E; Wiemann B; Starnes C; Scully S; Henley C; Martin D
Eur J Pharmacol; 2013 Jul; 712(1-3):8-15. PubMed ID: 23623934
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Carcinoma as a Cause of Humoral Hypercalcemia of Malignancy: A Case of a Patient With Elevated Parathyroid Hormone-Related Protein.
Christensen BR; Rendo MJ; Beeler BW; Huddleston BJ; Fenderson JL
Cureus; 2022 Mar; 14(3):e23398. PubMed ID: 35481321
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Takeuchi Y; Takahashi S; Miura D; Katagiri M; Nakashima N; Ohishi H; Shimazaki R; Tominaga Y
J Bone Miner Metab; 2017 Nov; 35(6):616-622. PubMed ID: 27873072
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature.
Koca SB
Turk J Pediatr; 2023; 65(5):853-861. PubMed ID: 37853976
[TBL] [Abstract][Full Text] [Related]
7. [Long-term efficacy and safety of treatment with cinacalcet in hypercalcemic persistent secondary hyperparathyroidism in renal transplant].
Massimetti C; Di Napoli A; Feriozzi S
G Ital Nefrol; 2022 Jun; 39(3):. PubMed ID: 35819043
[No Abstract] [Full Text] [Related]
8. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.
Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC
J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539
[TBL] [Abstract][Full Text] [Related]
9. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
10. Hypercalcemia of malignancy: a study of clinical features and relationships among circulating levels of calcium, parathyroid hormone and parathyroid hormone-related peptide.
Sriussadaporn S; Phoojaroenchanachai M; Ploybutr S; Plengvidhya N; Peerapatdit T; Nitiyanant W; Vannasaeng S; Vichayanrat A
J Med Assoc Thai; 2007 Apr; 90(4):663-71. PubMed ID: 17487119
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
[TBL] [Abstract][Full Text] [Related]
12. Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
Henrich LM; Rogol AD; D'Amour P; Levine MA; Hanks JB; Bruns DE
Clin Chem; 2006 Dec; 52(12):2286-93. PubMed ID: 17105782
[TBL] [Abstract][Full Text] [Related]
13. Hypercalcemia associated with squamous cell carcinoma of tongue.
Gavrila A; Hasinski S; Rose LI
Endocr Pract; 2001; 7(6):459-62. PubMed ID: 11747283
[TBL] [Abstract][Full Text] [Related]
14. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride.
Sloand JA; Shelly MA
Am J Kidney Dis; 2006 Nov; 48(5):832-7. PubMed ID: 17060004
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Persistent Hypercalcemia and Hyperparathyroidism With Cinacalcet After Successful Kidney Transplantation.
Ważna-Jabłońska E; Gałązka Z; Durlik M
Transplant Proc; 2016 Jun; 48(5):1623-5. PubMed ID: 27496458
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review.
Sheehan M; Tanimu S; Tanimu Y; Engel J; Onitilo A
Case Rep Oncol; 2020; 13(1):321-329. PubMed ID: 32308599
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet corrects hypercalcemia in mice with an inactivating Gα11 mutation.
Howles SA; Hannan FM; Gorvin CM; Piret SE; Paudyal A; Stewart M; Hough TA; Nesbit MA; Wells S; Brown SD; Cox RD; Thakker RV
JCI Insight; 2017 Oct; 2(20):. PubMed ID: 29046478
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.
Silverberg SJ; Rubin MR; Faiman C; Peacock M; Shoback DM; Smallridge RC; Schwanauer LE; Olson KA; Klassen P; Bilezikian JP
J Clin Endocrinol Metab; 2007 Oct; 92(10):3803-8. PubMed ID: 17666472
[TBL] [Abstract][Full Text] [Related]
20. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
